top of page
Home
About
Leadership Team
Scientific Advisory Board
Leadership Team
Scientific Advisory Board
Science
Overview
RSLV-132
RSLV-145
Mechanism of Action
Publications
Overview
RSLV-132
RSLV-145
Mechanism of Action
Publications
Pipeline
Sjögren’s Disease
Systemic Lupus Erthyematosus
Critical Care
Sjögren’s Disease
Systemic Lupus Erthyematosus
Critical Care
News & Events
Company Overview
Company Overview
Contact
Menu
Close
News and Events
News and Events
News and Events
News and Events
May 28, 2025
Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients.
Read Press Release
May 13, 2024
Resolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study
Read Press Release
February 12, 2024
Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results
Read Press Release
November 14, 2022
Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial
Read Press Release
June 23, 2021
Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients
Read Press Release
December 8, 2020
RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial
Read Press Release
December 8, 2020
Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results
Read Press Release
July 22, 2019
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
Read Press Release
June 13, 2019
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
Read Press Release
June 10, 2019
Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Read Press Release
Meet Us at Upcoming Conferences
American College of Rheumatology Annual Conference
Chicago, IL
October 24-29
Learn More
Circulating Nucleic Acids in Serum and Plasma
Hong Kong
December 3-5
Learn More
Resolve Therapeutics Company Overview
Learn More
Home
About
Leadership Team
Scientific Advisory Board
Science
Overview
RSLV-132
RSLV-145
Mechanism of Action
Publications
Pipeline
Sjögren’s Disease
Systemic Lupus Erthyematosus
Critical Care
News & Events
Company Overview
Contact
bottom of page
